Oncolytics Biotech Inc T.ONC

SABC 2024 - Irene Study Results - Pelareorep in TNBC

[Noteable]

Poster Session 1

12:30 – 2:00 p.m.

Wednesday, December 11

P1-09-19: IRENE study: Phase 2 study of oncolytic virus pelareorep and PD-1 inhibitor retifanlimab in metastatic triple negative breast  cancer - Principal Investigator: Mridula George

[Noteable]

T cell exhaustion contributes to therapeutic resistance of TNBC to PD-1/PD-L1 inhibitors. Continuous exposure of T cells to tumor antigens and suppressive cytokines (IL-10, TGF-β) leads to T cell exhaustion, which results in a poor response to immunotherapy and therapeutic resistance. The accumulated reactive oxyens species (ROS), increased HIF-α and activated calcium-calcineurin-NFAT signaling

[Noteable]

During hypoxic conditions, cells undergo critical adaptive responses that include the up-regulation of hypoxia-inducible proteins (HIFs) and the induction of the unfolded protein response (UPR). ONCY's pelareorep down-regulates HIF-1α levels and in so doing remodels the tumor microenvironment (TME) for sequential immune checkpoint inhibition.

[Noteable]

"  Background: Triple negative breast cancer (TNBC) is an aggressive subtype accounting for 15% of all breast cancer subtypes. It is characterized by larger tumor size, higher grade, early peak of recurrence, and a worse 5-year overall survival rate compared to other breast cancer subtypes. Treatment with immunotherapy has been shown to be beneficial in PD-L1 positive patients

[Noteable]

"Prior clinical studies have shown that pelareorep upregulates tumor PD-L1 expression and reverses immunosuppressive TMEs,” said Mridula George, M.D., Medical Oncologist, Rutgers Cancer Institute of New Jersey, Assistant Professor of Medicine, Rutgers Robert Wood Johnson Medical School, and principal investigator of the trial. “These findings suggest that pelareorep can address a pressing

[canadafan]

Very little has been said about the IRENE study. that was initiated alongside Incyte. adding to the ongoing relationship with Roche. imho, lots of excitement ahead.